TScan Therapeutics reported revenue of $1.05M and net income of -$30.40M for the quarter ended Jun 2026, down 65.8% year over year. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 19.88M | 11.66M | 23.97M | 24.06M | 24.07M | 24.05M | 24.23M | 47.21M | 94.83M | 65.60M | 94.88M | 113.43M | 118.70M | 111.99M | 129.68M | 129.73M | 129.84M | 129.78M | 129.91M | 129.95M | |||||
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 2.41M | 2.85M | 3.02M | 4.06M | 3.36M | 3.10M | 6.80M | 3.15M | 3.89M | 7.21M | 0.57M | 0.54M | 1.05M | 0.67M | 2.17M | 3.08M | 2.51M | 2.57M | 0.98M | 1.05M | |||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 14.21M | 12.61M | 14.69M | 14.49M | 15.03M | 15.60M | 21.78M | 21.23M | 22.74M | 22.41M | 24.86M | 26.88M | 26.26M | 29.35M | 29.79M | 32.63M | 31.69M | 20.04M | 21.90M | 23.40M | |||||
| Selling, General & AdministrativeSG&A | 4.05M | 4.45M | 4.49M | 4.81M | 4.91M | 6.14M | 7.77M | 6.53M | 5.89M | 6.16M | 7.08M | 7.77M | 7.41M | 8.02M | 8.63M | 9.10M | 7.87M | 6.39M | 8.22M | 8.14M | |||||
| Operating ExpensesOpex | 18.25M | 17.06M | 19.18M | 19.30M | 19.94M | 21.74M | 29.55M | 27.76M | 28.64M | 28.57M | 31.94M | 34.65M | 33.67M | 37.38M | 38.42M | 41.73M | 39.56M | 26.43M | 30.12M | 31.54M | |||||
| Operating IncomeOp. Inc | -15.84M | -14.20M | -16.16M | -15.25M | -16.58M | -18.65M | -22.74M | -24.61M | -24.75M | -21.36M | -31.37M | -34.11M | -32.62M | -36.71M | -36.25M | -38.65M | -37.05M | -23.86M | -29.14M | -30.49M | |||||
| EBIT | -15.84M | -14.20M | -16.16M | -15.25M | -16.58M | -18.65M | -22.74M | -24.61M | -24.75M | -21.36M | -31.37M | -34.11M | -32.62M | -36.71M | -36.25M | -38.65M | -37.05M | -23.86M | -29.14M | -30.49M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.20M | 0.97M | 0.96M | 0.97M | 0.98M | 0.85M | 0.96M | 0.95M | 0.96M | 0.78M | 0.68M | 0.69M | 0.70M | 0.70M | 0.69M | 0.70M | |||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.00M | 0.01M | 0.15M | 0.53M | 0.90M | 1.14M | 1.53M | 2.73M | 2.60M | 2.19M | 3.40M | 3.69M | 2.78M | 2.80M | 2.39M | 2.04M | 1.58M | 1.16M | 0.83M | |||||
| Other Non Operating IncomeOther Non Op Inc. | 0.01M | 0.15M | 0.33M | -0.07M | 0.18M | 0.56M | 1.75M | 1.74M | 1.23M | 2.45M | 2.73M | 0.90M | 2.12M | 1.70M | 1.34M | 0.88M | 0.47M | 0.13M | |||||||
| Net income details | |||||||||||||||||||||||||
| EBT | -15.84M | -14.20M | -16.16M | -15.10M | -16.25M | -18.72M | -22.56M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -34.72M | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M | -30.36M | |||||
| Profit After TaxPAT | -15.84M | -14.20M | -16.20M | -15.10M | -16.25M | -18.72M | -22.60M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -35.80M | -34.18M | -37.00M | -35.71M | -23.02M | -28.70M | -30.40M | |||||
| Income from Continuing OperationsIncome (Continuing) | -15.84M | -14.20M | -16.16M | -15.10M | -16.25M | -18.72M | -22.56M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -34.72M | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M | -30.36M | |||||
| Consolidated Net IncomeConsol Net Inc. | -15.84M | -14.20M | -16.16M | -15.10M | -16.25M | -18.72M | -22.56M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -34.72M | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M | -30.36M | |||||
| Income towards Parent CompanyParent Net Inc | -15.84M | -14.20M | -16.16M | -15.10M | -16.25M | -18.72M | -22.56M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -34.72M | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M | -30.36M | |||||
| Net Income towards Common StockholdersNet Income | -15.84M | -14.20M | -16.16M | -15.10M | -16.25M | -18.72M | -22.56M | -24.05M | -23.00M | -19.61M | -30.14M | -31.66M | -29.89M | -34.72M | -34.13M | -36.95M | -35.71M | -22.98M | -28.67M | -30.36M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.80 | -1.22 | -0.67 | -0.63 | -0.67 | -0.78 | -0.93 | -0.51 | -0.24 | -0.30 | -0.32 | -0.28 | -0.25 | -0.31 | -0.26 | -0.28 | -0.28 | -0.18 | -0.22 | -0.23 | |||||
| EPS (Diluted) | -0.80 | -1.22 | -0.67 | -0.63 | -0.67 | -0.78 | -0.93 | -0.51 | -0.24 | -0.30 | -0.32 | -0.28 | -0.25 | -0.31 | -0.26 | -0.28 | -0.28 | -0.18 | -0.22 | -0.23 | |||||
| Shares Outstanding | 19.88M | 11.66M | 23.97M | 24.06M | 24.07M | 24.05M | 24.23M | 47.21M | 94.83M | 65.60M | 94.88M | 113.43M | 118.70M | 111.99M | 129.68M | 129.73M | 129.84M | 129.78M | 129.91M | 129.95M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 19.88M | 11.66M | 23.97M | 24.06M | 24.07M | 24.05M | 24.23M | 47.21M | 94.83M | 65.60M | 94.88M | 113.43M | 118.70M | 111.99M | 129.68M | 129.73M | 129.84M | 129.78M | 129.91M | 129.95M | |||||
| EBITDA | -15.84M | -14.20M | -16.16M | -15.25M | -16.58M | -18.65M | -22.74M | -24.61M | -24.75M | -21.36M | -31.37M | -34.11M | -32.62M | -36.71M | -36.25M | -38.65M | -37.05M | -23.86M | -29.14M | -30.49M | |||||
| Interest ExpensesInt Expense | 0.20M | 0.97M | 0.96M | 0.97M | 0.98M | 0.85M | 0.96M | 0.95M | 0.96M | 0.78M | 0.68M | 0.69M | 0.70M | 0.70M | 0.69M | 0.70M |